Understanding Hormone Receptor-Positive Breast Cancer
Hormone receptors (ER/PR) are proteins on breast cancer cells that respond to estrogen and progesterone, driving tumor growth. ER/PR-positive cancers are defined by estrogen receptor (ER) expression ≥1% and/or progesterone receptor (PR) expression on immunohistochemistry.
Clinical significance: ER/PR-positive breast cancer comprises ~65-70% of all breast cancers and generally has better prognosis than HER2+ or triple-negative subtypes. 5-year survival for Stage III ER+ disease exceeds 85% with modern endocrine therapy and chemotherapy combinations.
Standard treatment:
- Early-stage (adjuvant): Chemotherapy (if high-risk) + endocrine therapy (tamoxifen, aromatase inhibitors) for 5-10 years. CDK4/6 inhibitors increasingly added for high-risk disease.
- Metastatic: Endocrine therapy ± CDK4/6 inhibitor as first-line. Upon progression, switch endocrine agent, add mTOR inhibitor, or switch to chemotherapy. Emerging trials test PARP inhibitors, PI3K inhibitors, and next-generation endocrine agents.
ER/PR Expression Levels
ER/PR status is quantified by the percentage of cells expressing hormone receptors (H-score) or Allred score:
Endocrine Therapy and Emerging Combinations
Aromatase inhibitors (AI): Block estrogen production in postmenopausal women. Letrozole, anastrozole, exemestane are standard first-line. Trials test AI combinations with CDK4/6 inhibitors, mTOR inhibitors, or novel agents.
CDK4/6 inhibitors: Palbociclib, ribociclib, abemaciclib + endocrine therapy now FDA-approved first-line for metastatic ER+ breast cancer. Trials test novel CDK inhibitors, combinations with other targeted agents, and de-escalation approaches for low-risk disease.
PIK3CA mutations and PI3K inhibitors: ~40% of ER+ breast cancers harbor PIK3CA mutations. Alpelisib (PI3K inhibitor) + hormone therapy improves survival in PIK3CA-mutant ER+ disease. Trials test next-generation PI3K inhibitors and combinations.
Resistance mechanisms: ESR1 mutations (acquired after endocrine therapy progression) predict fulvestrant benefit. BRCA mutations in ER+ disease may predict PARP inhibitor benefit.
Ready to explore ER/PR-positive trials matching your profile?
Upload your pathology report, treatment history, and imaging. We'll match you to recruiting trials and explain your eligibility for each.
ER/PR-Positive Breast Cancer & Trials
ER/PR-positive (estrogen receptor / progesterone receptor positive) means your breast cancer cells express proteins that respond to the hormones estrogen and/or progesterone, which drive tumor growth.
These cancers are hormone-dependent and respond well to endocrine therapy (hormone-blocking drugs). Approximately 2 out of 3 breast cancers are ER+ and generally have better prognosis than HER2+ or triple-negative disease.
Multiple endocrine therapy options exist:
Switch to aromatase inhibitor (AI): Letrozole, anastrozole, or exemestane — often effective if you haven't received them.
Add CDK4/6 inhibitor: Palbociclib, ribociclib, or abemaciclib plus new endocrine therapy improves progression-free survival.
Fulvestrant (selective ER degrader): Destroys ER protein; often combined with CDK4/6 inhibitor.
Chemotherapy: If hormone-refractory after multiple endocrine therapies.
Increasingly yes. ~40% of ER+ breast cancers have PIK3CA mutations. Alpelisib (PI3K inhibitor) + endocrine therapy improves survival in PIK3CA-mutant disease and is becoming standard of care in metastatic settings.
Ask your oncologist about PIK3CA testing — if positive, you qualify for trials testing alpelisib or next-generation PI3K inhibitors.
Yes, absolutely. Bone metastases are common in ER+ breast cancer and are actually favorable prognostically — bone-only disease tends to have slower progression than visceral metastases.
Most ER+ metastatic trials enroll patients with bone involvement. Bone-directed agents (bisphosphonates, denosumab) are often combined with systemic therapy.
Early-stage: Typically 5-10 years of endocrine therapy (tamoxifen for 5 years, or AI + tamoxifen combinations for 5-10 years).
Metastatic: Continuous until intolerance or progression. Emerging trials test de-escalation strategies and intermittent dosing to improve quality of life.
(1) Pathology report confirming ER/PR status (percentage and H-score or Allred score).
(2) PIK3CA and other mutation testing if available (increasingly standard).
(3) Prior endocrine therapy history with dates and response (duration on each agent, when progression occurred).
(4) Imaging reports (CT, bone scan, MRI) showing current metastatic sites.
(5) Liver/kidney function and ECOG performance status.